AI therapeutics announces start of Phase II Trial of LAM-002A (apilimod dimesylate) for treatment of COVID-19 patients

(CG Life) AI Therapeutics announced the start of Phase II clinical trial forthe treatment of newly diagnosed COVID-19 patients in collaboration with Yale University.